Back to results
US 2026/0209218 A1Published application
3-phenylquinazolinones as novel anti-cancer therapy
AssigneeHelmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)
InventorsMarcus CONRAD, Toshitaka NAKAMURA, Bettina PRONETH, Peter C. SENNHENN
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel 3-Phenylquinazolinones in particular for the use in the treatment of cancer.
Claims10
A compound according to formula (I) or (II), preferably formula (I) for use in the treatment of cancer,
- wherein G is selected from the group consisting of
- preferably
- M is selected from the group consisting of
- preferably
- Z is selected from the group consisting of CH, C—(C1-C6)alkyl, and N, preferably CH;
- A is selected from the group consisting of CH, C—(C1-C6)alkyl, and N, preferably CH;
- Q is selected from the group consisting of CH, C—(C1-C6)alkyl, and N, preferably CH;
- E is selected from the group consisting of —CO—, —SO2—, preferably —CO—;
- L is selected from the group consisting of CH, N, C—F, C—Cl, and C—(C1-C6)alkyl, preferably CH;
- X is selected from the group consisting of CH, N, C—F, C—Cl, and C—(C1-C6)alkyl, preferably CH;
- Y is selected from the group consisting of CH, N, C—F, C—Cl, and C—(C1-C6)alkyl, preferably CH;
- X and Y may be part of ring according to formula (III):
- n is an integer from 1 to 3;
- J is selected from the group consisting of CH, N, C—F, C—Cl, C—(C1-C6)alkyl, preferably CH;
- D1, D2, D3, D4, D5, are independently selected from the group consisting of C and N;
- R1 is selected from the group consisting of —(C1-C6)alkyl, —(C3-C6)cycloalkyl, —CH2OH, —CH2F, —CHF2, and —CF3, preferably —(C1-C6)alkyl;
- R2 is selected from the group consisting of H, —(C1-C6)alkyl, —CF3, —Cl, and —F, preferably H;
- R3 is selected from the group consisting of H, —(C1-C6)alkyl, —CF3, —O(C1-C6)alkyl, —Cl, and —F, preferably —O(C1-C6)alkyl;
- R4 is selected from the group consisting of H, —(C1-C6)alkyl, —O(C1-C6)alkyl, —CF3, —Cl, and —F, preferably —O(C1-C6)alkyl;
- R5 is selected from the group consisting of H, —(C1-C6)alkyl, —O(C1-C6)alkyl, —CF3, —C, and —F, preferably —O(C1-C6)alkyl;
- R6 is selected from the group consisting of H, —(C1-C6)alkyl, —CF3, —Cl, and —F, preferably H;
- two groups of R2, R3, R4, R5 and R6 in vicinal position may be part of a ring selected from
- o is an integer between 1 and 4;
- p is an integer between 1 and 4;
- q is 1 or 0;
- R7 and R8 are independently selected from the group consisting of H, and —(C1-C6)alkyl;
- R7 and R8 may form a 3 to 5 membered cycloalkyl ring;
- R9 is selected from the group consisting of H, and —(C1-C6)alkyl or
- a pharmaceutically acceptable salt thereof.
26 more elements
A compound according to formula (I), or (II)
- wherein G is selected from the group consisting of
- preferably
- M is selected from the group consisting of
- preferably
- Z is selected from the group consisting of CH, C—(C1-C6)alkyl, and N, preferably CH;
- A is selected from the group consisting of CH, C—(C1-C6)alkyl, and N, preferably CH;
- Q is selected from the group consisting of CH, C—(C1-C6)alkyl, and N, preferably CH;
- E is selected from the group consisting of —CO—, —SO2—, preferably —CO—;
- L is selected from the group consisting of CH, N, C—F, C—Cl, and C—(C1-C6)alkyl, preferably CH;
- X is selected from the group consisting of CH, N, C—F, C—Cl, and C—(C1-C6)alkyl, preferably CH;
- Y is selected from the group consisting of CH, N, C—F, C—Cl, and C—(C1-C6)alkyl, preferably CH;
- X and Y may be part of a ring according to formula (III):
- n is an integer from 1 to 3;
- J is selected from the group consisting of CH, N, C—F, C—Cl, C—(C1-C6)alkyl, preferably CH;
- D1, D2, D3, D4, D5, are independently selected from the group consisting of C and N;
- R1 is selected from the group consisting of —(C1-C6)alkyl, —(C3-C6)cycloalkyl, —CH2OH, —CH2F, —CHF2, and —CF3, preferably —(C1-C6)alkyl;
- R2 is selected from the group consisting of H, —(C1-C6)alkyl, CF3, —Cl, and —F, preferably H;
- R3 is selected from the group consisting of H, —(C1-C6)alkyl, —O(C1-C6)alkyl, CF3, —Cl, and —F, preferably —O(C1-C6)alkyl;
- R4 is selected from the group consisting of H, —(C1-C6)alkyl, —O(C1-C6)alkyl, CF3, —Cl, and —F, preferably —O(C1-C6)alkyl;
- R5 is selected from the group consisting of H, —(C1-C6)alkyl, —O(C1-C6)alkyl, CF3, —Cl, and —F, preferably —O(C1-C6)alkyl;
- R6 is selected from the group consisting of H, —(C1-C6)alkyl, CF3, —Cl, and —F, preferably H;
- two groups of R2, R3, R4, R5 and R6 in vicinal position may be part of a ring selected from
- o is an integer between 1 and 4;
- p is an integer between 1 and 4;
- q is 0 or 1;
- R7 and R8 are independently selected from the group consisting of H, and —(C1-C6)alkyl;
- R7 and R8 may form a 3 to 5 membered cycloalkyl;
- R9 is selected from the group consisting of H, and —(C1-C6)alkyl or
- a pharmaceutically acceptable salt thereof,
- with the provision that the compound is not selected from the group consisting of
- or a pharmaceutically acceptable salt thereof.
28 more elements
Dependencies are inferred from the claim text.